WO2025210517 - HUMANIZED ANTI-CD40 ANTIBODIES FOR TREATING SJÖGREN'S DISEASE
National phase entry is expected:
Publication Number
WO/2025/210517
Publication Date
09.10.2025
International Application No.
PCT/IB2025/053431
International Filing Date
01.04.2025
Title **
[English]
HUMANIZED ANTI-CD40 ANTIBODIES FOR TREATING SJÖGREN'S DISEASE
[French]
ANTICORPS ANTI-CD40 HUMANISÉS POUR LE TRAITEMENT DE LA MALADIE DE SJÖGREN
Applicants **
KINIKSA PHARMACEUTICALS, GMBH
Inventors
PAOLINI, John F.
TESSARI, Eben
Priority Data
63/573,186
02.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4191 | |
| EPO | Filing, Examination, Granting | 60858 | |
| Japan | Filing, Examination, Granting | 4066 | |
| South Korea | Filing, Examination, Granting | 5818 | |
| USA | Filing, Examination, Granting | 15940 |
Total:
90,873
Contact Us
Abstract[English]
The present disclosure relates to dosing regimens of pharmaceutical compositions of anti- CD40 antibodies, such as humanized anti-CD40 antibodies, and uses thereof in the treatment of Sjögren's disease.[French]
La présente invention concerne des schémas posologiques de compositions pharmaceutiques d'anticorps anti-CD40, tels que des anticorps anti-CD40 humanisés, et leurs utilisations dans le traitement de la maladie de Sjögren.